Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMG-7289 · 2 trials · 3 indications
As evaluated by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Leukemia Net (ELN) response criteria.
ELN criteria
| Arm | Type | Description |
|---|---|---|
| IMG-7289 in ET and PV Patients | EXPERIMENTAL | Oral daily dose of 0.6 mg/kg/day IMG-7289 will be administered: * The initial pilot period will enroll 8 participants to receive oral daily dose of IMG-7829 for 24 weeks, iteratively as long as there is clinical benefit in the absence of excess toxicity. * The second stage group will enroll an additional 16 participants to receive IMG-7829 for over 2 years, iteratively as long as there is clinical benefit in the absence of toxicity. |
| IMG-7289 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| IMG-7289 | DRUG | Daily oral dose of 0.6 mg/kg/day IMG-7829 capsules. Dose escalation an de-escalation rules applied as necessary. |
Inclusion Criteria: 1. Age ≥ 18 years. 2. Diagnosis of Essential Thrombocythemia or Polycythemia Vera per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms (Arber et al., 2016). 3. Patients that have failed at least one standard therapy (failure is the equivalent ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Bomedemstat, Hydroxyurea |
| Incyte Corporation | INCY | 1 | PHASE1 | INCB057643, Ruxolitinib |
IMG-7289 is an investigational small molecule being studied for the treatment of essential thrombocythemia (ET), a blood disorder characterized by an elevated platelet count. It is currently in Phase 2 clinical development for this condition. The drug is also being investigated in patients with polycythemia vera (PV), another myeloproliferative neoplasm.
IMG-7289 targets LSD1 (lysine-specific demethylase 1), an enzyme involved in epigenetic regulation. By inhibiting LSD1, the drug may alter gene expression related to blood cell production. This mechanism is being explored in essential thrombocythemia and polycythemia vera, where abnormal blood cell proliferation occurs.
IMG-7289 is being developed by Merck & Company, Inc., a global biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 2 clinical trials for hematologic conditions, including essential thrombocythemia.
IMG-7289 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing trials are active but not recruiting participants, indicating that enrollment has been completed and the studies are continuing to evaluate the drug's safety and efficacy.
IMG-7289 is being studied in two Phase 2 clinical trials. NCT04081220 is evaluating the drug in patients with essential thrombocythemia, with an enrollment of 9 participants. NCT04262141 is investigating IMG-7289 in patients with essential thrombocythemia or polycythemia vera, with an enrollment of 4 participants. Both trials are active but not recruiting.
IMG-7289 is also known as bomedemstat, an alternative name for the drug. It is an LSD1 inhibitor being developed by Merck & Company, Inc. for the treatment of myeloproliferative neoplasms, including essential thrombocythemia and polycythemia vera.